In the Rare Oncology Agnostic Research (ROAR) study, BRAFi dabrafenib with or without trametinib (a MEK inhibitor, MEKi) was evaluated in 45 patients with BRAF-mutated high-grade glioma (HGG, 31 diagnosed as GBM) [94]. This evidence concerns the gene BRAF and central nervous system cancer.